<DOC>
	<DOCNO>NCT02119676</DOCNO>
	<brief_summary>The purpose study determine ruxolitinib , combination regorafenib , safe effective treatment metastatic colorectal cancer .</brief_summary>
	<brief_title>Study Ruxolitinib Colorectal Cancer Patients</brief_title>
	<detailed_description>The study consist open-label , Part 1 safety run-in ( consist 1 3 cohort 9 subject ) , confirm safety regorafenib/ruxolitinib combination subject relapse refractory metastatic colorectal cancer ( CRC ) . If determine tolerable , Part 2 proceed randomize , double-blind study evaluate ruxolitinib placebo combination regorafenib subject relapse refractory metastatic CRC previously treat fluoropyrimidine , oxaliplatin , and/or irinotecan base chemotherapy , anti-vascular endothelial growth factor ( VEGF ) therapy Kirsten rat sarcoma ( KRAS ) wild type anti-epidermal growth factor receptor ( EGFR ) therapy . Subjects safety run-in receive open-label ruxolitinib regorafenib ; randomize , double-blind portion study subject receive regorafenib either ruxolitinib placebo 1:1 blind manner . Treatment subject consist repeat 28-day cycle . Regorafenib self-administered first 21 day cycle , ruxolitinib/placebo self-administered entire 28-day cycle . Treatment cycle continue long regimen tolerate , subject meet discontinuation criterion . When subject discontinue regorafenib , ruxolitinib placebo remain study follow subsequent treatment regimen initiate survival .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma colon rectum metastatic . Previous treatment fluoropyrimidine , oxaliplatin irinotecan base chemotherapy , antiVEGF therapy ( contraindication ) KRAS wild type contraindication , antiEGFR therapy . Radiographically measurable evaluable disease ( per RECIST v1.1 ) Life expectancy ≥ 12 week . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Three week elapse completion previous treatment regimen subject must recover new stable baseline relate toxicity . Prior radiotherapy disease sit allow certain protocoldefined restriction . Prior treatment regorafenib . Presence active gastrointestinal disease condition interfere significantly absorption drug . Active peptic ulcer disease , inflammatory bowel disease ( eg , ulcerative colitis , Crohn 's disease ) , diverticulitis , gastrointestinal condition increase risk perforation gastrointestinal bleeding . Recent history ( ≤ 3 month ) ongoing partial complete bowel obstruction unless due disease study correct surgery . Blood pressure ≥ 140/90 mmHg . Active bleeding diathesis history major bleeding ( eg , require transfusion red blood cell ( RBCs ) , central nervous system ( CNS ) bleeding , significant hemoptysis within 6 month enrollment . Subjects bleed secondary underlying disease ( include gastrointestinal ( GI ) perforation fistula ) correct surgery alternative procedure may include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Ruxolitinib</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>regorafenib</keyword>
	<keyword>Jakavi ®</keyword>
	<keyword>Jakafi ®</keyword>
	<keyword>Stivarga ®</keyword>
</DOC>